Researchers from Georgia State University in the US discovered that serotonin (5-HT) and arginine-vasopressin (AVP) act in opposite ways in males and females to influence aggression and dominance.
Since dominance and aggressiveness have been linked to stress resistance, the findings may influence the development of more effective gender-specific treatment strategies for stress-related neuropsychiatric disorders.
“These results begin to provide a neurochemical basis for understanding how the social brain works quite differently in males and females,” said Elliott Albers, professor at Georgia State University.
Prominent sex differences occur in the incidence, development and clinical course of many neuropsychiatric disorders.
Women, for example, have higher rates of depression and anxiety disorders such as posttraumatic stress disorder (PTSD), while men more frequently suffer from autism and attention deficit disorder.
Despite profound sex differences in the expression of social behaviour and the incidence of these psychiatric disorders, little is known about how the brain mechanisms underlying these phenomena differ in females and males.
Limited knowledge exists regarding sex differences in the efficacy of treatments for these disorders. As a result, current treatment strategies are largely the same for both sexes.
In this study conducted in hamsters, researchers tested the hypothesis that 5-HT promotes and AVP inhibits aggression and dominance in females and that 5-HT inhibits and AVP promotes aggression and dominance in males.
Their data show strong support for this hypothesis with the discovery that 5-HT and AVP act in opposite ways within the hypothalamus to regulate dominance and aggression in females and males.
The study also found that administration of the 5-HT reuptake inhibitor fluoxetine, one of the most commonly prescribed drugs for psychiatric disorders, increased aggression in females and inhibited aggression in males.
These studies raise the possibility that stress-related neuropsychiatric disorders such as PTSD may be more effectively treated with 5-HT-targeted drugs in women and with AVP-targeted drugs in men.
The study appears in the journal PNAS.
PTI